{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:49Z","timestamp":1787030149283,"version":"build-2736575974"},"reference-count":92,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The rollout of COVID-19 vaccines brings hope for successful pandemic mitigation and getting the transmission of SARS-CoV-2 under control. The vaccines authorized in Europe displayed a good safety profile in the clinical trials. However, during their post-authorization use, unusual thrombotic events associated with thrombocytopenia have rarely been reported for vector vaccines. This led to the temporary suspension of the AZD1222 vaccine (Oxford\/AstraZeneca) in various European countries and the Ad26.COV2 vaccine (Janssen\/Johnson&amp;Johnson) in the United States, with regulatory bodies launching investigations into potential causal associations. The thromboembolic reactions were also rarely reported after mRNA vaccines. The exact cause of these adverse effects remains to be elucidated. The present paper outlines the hypotheses on the mechanisms behind the very rare thrombotic thrombocytopenia reported after the COVID-19 vaccination, along with currently existing evidence and future research prospects. The following are discussed: (i) the role of antibodies against platelet factor 4 (PF4), (ii) the direct interaction between adenoviral vector and platelets, (iii) the cross-reactivity of antibodies against SARS-CoV-2 spike protein with PF4, (iv) cross-reactivity of anti-adenovirus antibodies and PF4, (v) interaction between spike protein and platelets, (vi) the platelet expression of spike protein and subsequent immune response, and (vii) the platelet expression of other adenoviral proteins and subsequent reactions. It is also plausible that thrombotic thrombocytopenia after the COVID-19 vaccine is multifactorial. The elucidation of the causes of these adverse events is pivotal in taking precautionary measures and managing vaccine hesitancy. It needs to be stressed, however, that the reported cases are currently sporadic and that the benefits of COVID-19 vaccines vastly outweigh their potential risks.<\/jats:p>","DOI":"10.3390\/vaccines9060559","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T23:16:46Z","timestamp":1622157406000},"page":"559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4713-0801","authenticated-orcid":false,"given":"Piotr","family":"Rzymski","sequence":"first","affiliation":[{"name":"Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"},{"name":"Integrated Science Association (ISA), Universal Scientific Education and Research Network (USERN), 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-9571","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Perek","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, 61-848 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-1635","authenticated-orcid":false,"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-540 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Burgos, R.M., Badowski, M.E., Drwiega, E., Ghassemi, S., Griffith, N., Herald, F., Johnson, M., Smith, R.O., and Michienzi, S.M. (2021). The race to a COVID-19 vaccine: Opportunities and challenges in development and distribution. Drugs Context, 10.","DOI":"10.7573\/dic.2020-12-2"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Defendi, H.G.T., da Silva Madeira, L., and Borschiver, S. (2021). Analysis of the COVID-19 Vaccine Development Process: An Exploratory Study of Accelerating Factors and Innovative Environments. J. Pharm. Innov.","DOI":"10.1007\/s12247-021-09535-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"110451","DOI":"10.1016\/j.biopha.2020.110451","article-title":"When science goes viral: The research response during three months of the COVID-19 outbreak","volume":"129","author":"Nowakowska","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A.M., Stoop, J., Tete, S., Van Damme, W., and Leroux-Roels, I. (2021). Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2034201"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine development for emerging infectious diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rzymski, P., Borkowski, L., Dr\u0105g, M., Flisiak, R., Jemielity, J., Krajewski, J., Mastalerz-Migas, A., Matyja, A., Pyr\u0107, K., and Simon, K. (2021). The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. Vaccines, 9.","DOI":"10.3390\/vaccines9020109"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rzymski, P., Zeyland, J., Poniedzia\u0142ek, B., Ma\u0142ecka, I., and Wysocki, J. (2021). The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland. Vaccines, 9.","DOI":"10.3390\/vaccines9040382"},{"key":"ref_11","unstructured":"(2021, April 19). European Medicines Agency. AstraZeneca\u2019s COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Blood Platelets. Available online: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/jth.14210","article-title":"Cerebral venous sinus thrombosis","volume":"16","author":"Capecchi","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1161\/STROKEAHA.112.671453","article-title":"The incidence of cerebral venous thrombosis: A cross-sectional study","volume":"43","author":"Coutinho","year":"2012","journal-title":"Stroke"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/STROKEAHA.116.013617","article-title":"Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study","volume":"47","author":"Devasagayam","year":"2016","journal-title":"Stroke"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/VHRM.S197732","article-title":"Splanchnic Vein Thrombosis: Current Perspectives","volume":"15","author":"Valeriani","year":"2019","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"n699","DOI":"10.1136\/bmj.n699","article-title":"Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"ref_17","first-page":"n1114","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study","volume":"373","author":"Lund","year":"2021","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"n970","DOI":"10.1136\/bmj.n970","article-title":"Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots","volume":"373","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sadoff, J., Gray, G., Vandebosch, A., C\u00e1rdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truyers, C., Fennema, H., and Spiessens, B. (2021). Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2101544"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sadoff, J., Davis, K., and Douoguih, M. (2021). Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination\u2014Response from the Manufacturer. N. Engl. J. Med.","DOI":"10.1056\/NEJMc2106075"},{"key":"ref_21","unstructured":"Taquet, M., Husain, M., Geddes, J.R., Luciano, S., and Harrison, P.J. (2021, April 19). Cerebral Venous Thrombosis: A Retrospective Cohort Study of 513\u2009284 Confirmed COVID-19 Cases and a Comparison with 489\u2009871 People Receiving a COVID-19 mRNA Vaccine. Version 2. Available online: https:\/\/osf.io\/a9jdq\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n1005","DOI":"10.1136\/bmj.n1005","article-title":"Covid-19: Risk of cerebral blood clots from disease is 10 times that from vaccination, study finds","volume":"373","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Smadja, D.M., Yue, Q.-Y., Chocron, R., Sanchez, O., and Lillo-Le Louet, A. (2021). Vaccination against COVID-19: Insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur. Respir. J., 2100956.","DOI":"10.1183\/13993003.00956-2021"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1067\/mlc.2001.115525","article-title":"Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia\/thrombosis","volume":"138","author":"Visentin","year":"2001","journal-title":"J. Lab. Clin. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3109\/09537104.2014.979338","article-title":"Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: Atypical clinical features with heparin-dependent platelet activating antibodies","volume":"26","author":"Okata","year":"2015","journal-title":"Platelets"},{"key":"ref_28","first-page":"2124","article-title":"Spontaneous heparin-induced thrombocytopenia (HIT) syndrome: HIT without any heparin exposure","volume":"57","author":"Miyata","year":"2016","journal-title":"[Rinsho Ketsueki] Jpn. J. Clin. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Schultz, N.H., S\u00f8rvoll, I.H., Michelsen, A.E., Munthe, L.A., Lund-Johansen, F., Ahlen, M.T., Wiedmann, M., Aamodt, A.H., Skatt\u00f8r, T.H., and Tj\u00f8nnfjord, G.E. (2021). Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2104882"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Greinacher, A., Thiele, T., Warkentin, T.E., Weisser, K., Kyrle, P.A., and Eichinger, S. (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2104840"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Scully, M., Singh, D., Lown, R., Poles, A., Solomon, T., Levi, M., Goldblatt, D., Kotoucek, P., Thomas, W., and Lester, W. (2021). Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2105385"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Muir, K.-L., Kallam, A., Koepsell, S.A., and Gundabolu, K. (2021). Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. N. Engl. J. Med.","DOI":"10.1056\/NEJMc2105869"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2007-08-105098","article-title":"Determinants of PF4\/heparin immunogenicity","volume":"110","author":"Suvarna","year":"2007","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10717544.2017.1413450","article-title":"Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity","volume":"25","author":"Kim","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood-2013-01-478966","article-title":"Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4","volume":"122","author":"Jaax","year":"2013","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/intimm\/dxn142","article-title":"Serum DNase I, soluble Fas\/FasL levels and cell surface Fas expression in patients with SLE: A possible explanation for the lack of efficacy of hrDNase I treatment","volume":"21","author":"Tinazzi","year":"2009","journal-title":"Int. Immunol."},{"key":"ref_37","unstructured":"Curiel, D.T. (2016). 14-Innate Immune Response to Adenovirus Vector Administration In Vivo. Adenoviral Vectors for Gene Therapy, Academic Press. [2nd ed.]."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/hum.2004.15.1157","article-title":"The innate immune response to adenovirus vectors","volume":"15","author":"Muruve","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1515\/CCLM.2007.110","article-title":"The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes","volume":"45","author":"Banfi","year":"2007","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1076029610373367","article-title":"EDTA-dependent pseudothrombocytopenia in a child","volume":"17","author":"Akbayram","year":"2011","journal-title":"Clin. Appl. Thromb.\/Hemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3904\/kjim.2002.17.1.65","article-title":"EDTA-dependent pseudothrombocytopenia confirmed by supplementation of kanamycin; a case report","volume":"17","author":"Ahn","year":"2002","journal-title":"Korean J. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajh.2830360307","article-title":"EDTA-dependent pseudothrombocytopenia: A clinical study of 18 patients and a review of the literature","volume":"36","author":"Berkman","year":"1991","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajh.2830500206","article-title":"EDTA-dependent pseudothrombocytopenia: A clinical and epidemiological study of 112 cases, with 10-year follow-up","volume":"50","author":"Bizzaro","year":"1995","journal-title":"Am. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.V59.1.157.157","article-title":"Pseudothrombocytopenia: An immunologic study on platelet antibodies dependent on ethylene diamine tetra-acetate","volume":"59","author":"Pegels","year":"1982","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1182\/blood-2005-05-1938","article-title":"Anti-platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin","volume":"106","author":"Warkentin","year":"2005","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1161\/01.CIR.99.19.2530","article-title":"Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: Clinical implications for heparin-induced thrombocytopenia","volume":"99","author":"Pouplard","year":"1999","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/09537100075751","article-title":"Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia","volume":"11","author":"Horsewood","year":"2000","journal-title":"Platelets"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.V89.2.370","article-title":"Fc\u03b3RIIA H\/R131 Polymorphism, Subclass-Specific IgG Anti-Heparin\/Platelet Factor 4 Antibodies and Clinical Course in Patients with Heparin-Induced Thrombocytopenia and Thrombosis","volume":"89","author":"Arepally","year":"1997","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2014-09-594515","article-title":"Increased risk of thrombosis in Fc\u03b3RIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2","volume":"125","author":"Rollin","year":"2015","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.thromres.2011.09.033","article-title":"Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia","volume":"129","author":"Pouplard","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1309\/BMW4M8NQBV0TKFRX","article-title":"Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia","volume":"129","author":"Harris","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/1743-422X-8-456","article-title":"Human platelets express CAR with localization at the sites of intercellular interaction","volume":"8","author":"Gupalo","year":"2011","journal-title":"Virol. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"16756","DOI":"10.1038\/srep16756","article-title":"Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice","volume":"5","author":"Dicks","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1128\/JVI.00928-12","article-title":"Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys","volume":"86","author":"Li","year":"2012","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eaax3567","DOI":"10.1126\/sciadv.aax3567","article-title":"Human adenovirus type 26 uses sialic acid\u2013bearing glycans as a primary cell entry receptor","volume":"5","author":"Baker","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09537109109005496","article-title":"Sialic Acid: Its importance to platelet function in health and disease","volume":"2","author":"Crook","year":"1991","journal-title":"Platelets"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3892\/mmr.2013.1805","article-title":"Adenovirus type 3 induces platelet activation in vitro","volume":"9","author":"Jin","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1128\/JVI.02819-06","article-title":"Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the Liver","volume":"81","author":"Stone","year":"2007","journal-title":"J. Virol."},{"key":"ref_60","unstructured":"Shoenfeld, Y., Gershwin, M.E., and Meroni, P.L. (2007). Autoantibodies in heparin-induced thrombocytopenia. Autoantibodies, Elsevier. [2nd ed]."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","article-title":"Adenovirus-induced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance","volume":"109","author":"Othman","year":"2007","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first-generation adenoviral vector in rhesus macaques","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/(SICI)1521-2254(199909\/10)1:5<360::AID-JGM54>3.0.CO;2-Q","article-title":"Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits","volume":"1","author":"Cichon","year":"1999","journal-title":"J. Gene Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Muster, V., Gary, T., Raggam, R.B., W\u00d6lfler, A., and Brodmann, M. (2021). Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination. Lancet.","DOI":"10.1016\/S0140-6736(21)00871-0"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/09537104.2012.703792","article-title":"Platelet-adenovirus vs. inert particles interaction: Effect on aggregation and the role of platelet membrane receptors","volume":"24","author":"Gupalo","year":"2013","journal-title":"Platelets"},{"key":"ref_66","unstructured":"(2021, April 19). Medicines & Healthcare Products Regulatory Agency. Summary of the Public Assessment Report for AstraZeneca COVID-19 Vaccine, Available online: https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-astrazeneca\/summary-of-the-public-assessment-report-for-astrazeneca-covid-19-vaccine."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Sadrzadeh, H., and Kline, G. (2017). Variables affecting endocrine tests results, errors prevention and mitigation. Endocrine Biomarkers, Elsevier. Chapter 1.","DOI":"10.1016\/B978-0-12-803412-5.00001-X"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.bbrc.2005.10.088","article-title":"Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11","volume":"338","author":"Cheng","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases","volume":"217","author":"Vojdani","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100743","DOI":"10.1016\/j.blre.2020.100743","article-title":"The looming storm: Blood and cytokines in COVID-19","volume":"46","author":"Kaur","year":"2021","journal-title":"Blood Rev."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Greinacher, A., Selleng, K., Mayerle, J., Palankar, R., Wesche, J., Reiche, S., Aebischer, A., Warkentin, T.E., Muenchhoff, M., and Hellmuth, J.C. (2021). Anti-SARS-CoV-2 spike protein and anti-platelet factor 4 antibody responses induced by COVID-19 disease and ChAdOx1 nCov-19 vaccination. Res. Sq.","DOI":"10.21203\/rs.3.rs-404769\/v1"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Vogel, A.B., Kanevsky, I., Che, Y., Swanson, K.A., Muik, A., Vormehr, M., Kranz, L.M., Walzer, K.C., Hein, S., and G\u00fcler, A. (2020). A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv.","DOI":"10.1101\/2020.09.08.280818"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Watanabe, Y., Mendon\u00e7a, L., Allen, E.R., Howe, A., Lee, M., Allen, J.D., Chawla, H., Pulido, D., Donnellan, F., and Davies, H. (2021). Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19\/AZD1222 Vaccine. ACS Cent. Sci.","DOI":"10.1101\/2021.01.15.426463"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: Comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"ref_80","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Kobinger","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"118431","DOI":"10.1016\/j.lfs.2020.118431","article-title":"SARS-CoV-2 and coagulation disorders in different organs","volume":"260","author":"Vinayagam","year":"2020","journal-title":"Life Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"106895","DOI":"10.1016\/j.foodcont.2019.106895","article-title":"Is there an opportunity for product differentiation between GM and non-GM soya-based products in Argentina?","volume":"109","author":"Areal","year":"2020","journal-title":"Food Control"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e202000786","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Xu, S., Yang, K., Li, R., and Zhang, L. (2020). mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186582"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Gresele, P., Kleiman, N.S., Lopez, J.A., and Page, C.P. (2017). Virus\u2013Platelet Associations. Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: An Update, Springer International Publishing.","DOI":"10.1007\/978-3-319-47462-5"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2014-04-512756","article-title":"A tour through the transcriptional landscape of platelets","volume":"124","author":"Schubert","year":"2014","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Salunkhe, V., Papadopoulos, P., and Gutierrez, L. (2015). Culture of Megakaryocytes from Human Peripheral Blood Mononuclear Cells. Bio-Protocol, 5.","DOI":"10.21769\/BioProtoc.1639"},{"key":"ref_90","unstructured":"(2021, April 19). Medicines & Healthcare Products Regulatory Agency. Summary of the Public Assessment Report for Pfizer\/BioNTech COVID-19 Vaccine, Available online: https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19\/summary-public-assessment-report-for-pfizerbiontech-covid-19-vaccine."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4049\/jimmunol.1200580","article-title":"Platelets present antigen in the context of MHC class I","volume":"189","author":"Chapman","year":"2012","journal-title":"J. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13073-021-00859-1","article-title":"SARS-CoV-2 Vaccine ChAdOx1 nCoV-19 Infection Of Human Cell Lines Reveals Low Levels of Viral Backbone Gene Transcription Alongside Very High Levels of SARS-CoV-2 S Glycoprotein Gene Transcription","volume":"13","author":"Almuqrin","year":"2021","journal-title":"Genome Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/6\/559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:08:47Z","timestamp":1760162927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/6\/559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":92,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["vaccines9060559"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9060559","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]}}}